School of Pharmacy, Guangxi University of Chinese Medicine, Nanning, Guangxi, 530200, People's Republic of China.
National Engineering Research Center of Chinese Medicine Solid Preparation Manufacturing Technology, Nanchang, 330006, People's Republic of China.
Drug Des Devel Ther. 2022 May 12;16:1407-1431. doi: 10.2147/DDDT.S350886. eCollection 2022.
Ibuprofen (IBU), a nonsteroidal anti-inflammatory drug, shows poor gastrointestinal absorption due to its low solubility, which limits its clinical application.
In the present study, we aimed to develop thermosensitive gel-mediated ibuprofen-solid lipid nanoparticles (IBU-SLN-ISG) to improve the dissolution and bioavailability of IBU after rectal delivery.
IBU-loaded SLNs (IBU-SLNs) were developed and optimized applying Box-Behnken design. The optimized IBU-SLNs were characterized by physicochemical parameters and morphology. Then, the optimized IBU-SLNs was incorporated into the gel and characterized for gel properties and rheology and investigated its release in vitro, pharmacokinetics in vivo, rectal irritation and rectal retention time.
The optimized SLNs had an EE of 90.74 ± 1.40%, DL of 11.36 ± 1.20%, MPS of 166.77 ± 2.26 nm, PDI of 0.27 ± 0.08, and ZP of -21.00 ± 0.59 mV. The FTIR spectra confirmed successful encapsulation of the drug inside the nanoparticle as only peaks responsible for the lipid could be identified. This corroborated well with XRD spectra, which showed a completely amorphous state of the IBU-SLNs as compared to the crystalline nature of the pure drug. The gelation temperature of the prepared IBU-SLN-ISG was 33.30 ± 0.78°C, the gelation time was 14.67 ± 2.52 s, the gel strength was 54.00 ± 1.41 s, and the mucoadhesion was (11.54±0.37) × 10dyne/cm. The in vitro results of IBU-SLNs and IBU-SLN-ISG showed a biphasic release pattern with initial burst release followed by sustained release. More importantly, IBU-SLN-ISG produced much better absorption of IBU and improved bioavailability in rats. In addition, IBU-SLN-ISG caused no irritation or damage to rectal tissues, and could be retained in the rectum for a long time.
Thermosensitive in situ gel loaded with IBU-solid lipid nanoparticles might be further developed as a more convenient and effective rectal dosage form.
布洛芬(IBU)是一种非甾体抗炎药,由于其溶解度低,胃肠道吸收较差,限制了其临床应用。
本研究旨在开发热敏凝胶介导的布洛芬固体脂质纳米粒(IBU-SLN-ISG),以改善直肠给药后布洛芬的溶解和生物利用度。
采用 Box-Behnken 设计,制备并优化布洛芬载药 SLN(IBU-SLNs)。通过物理化学参数和形态对优化后的 IBU-SLNs 进行表征。然后,将优化后的 IBU-SLNs 加入凝胶中,对凝胶性质和流变学进行表征,并考察其体外释放、体内药代动力学、直肠刺激性和直肠滞留时间。
优化后的 SLNs 的 EE 为 90.74±1.40%,DL 为 11.36±1.20%,MPS 为 166.77±2.26nm,PDI 为 0.27±0.08,ZP 为-21.00±0.59mV。傅里叶变换红外光谱(FTIR)证实药物成功包封在纳米粒子内,只能识别出负责脂质的峰。这与 X 射线衍射(XRD)光谱很好地吻合,XRD 光谱显示 IBU-SLNs 处于完全无定形状态,而纯药物则呈结晶状态。制备的 IBU-SLN-ISG 的胶凝温度为 33.30±0.78°C,胶凝时间为 14.67±2.52s,凝胶强度为 54.00±1.41s,黏膜粘附力为(11.54±0.37)×10dyne/cm。IBU-SLNs 和 IBU-SLN-ISG 的体外结果表明,药物呈现出两相释放模式,初始突释后持续释放。更重要的是,IBU-SLN-ISG 使 IBU 的吸收更好,提高了大鼠的生物利用度。此外,IBU-SLN-ISG 对直肠组织无刺激性和损伤,能在直肠内长时间滞留。
载布洛芬固体脂质纳米粒的热敏原位凝胶可能进一步开发为更方便、有效的直肠给药剂型。